METHODS	In 83 patients randomised to receive subcutaneous teduglutide 0.10 mg/kg/day ( n = 32 ) , 0.05 mg/kg/day ( n = 35 ) or placebo ( n = 16 ) once daily , parenteral fluids were reduced at 4-week intervals if intestinal fluid absorption ( 48 h urine volumes ) increased 10 % .\